Newsletter Tool

PM Tracker

Today’s Big News

Apr 18, 2024

AbbVie-bound Cerevel reports phase 3 Parkinson's victory in early win for $8.7B deal

Novo Nordisk attracts lawmakers' scrutiny after dropping discounted insulin product Levemir

23andMine: CEO Anne Wojcicki aims to take genetics company private

AACR: Biotechs emerge frostbitten from ‘nuclear winter,’ ready to show why they fought for survival

Lilly's Mounjaro, Zepbound supply situation worsens as most doses now face multi-month shortages

With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments

Biopharma M&A more than doubled in the first quarter compared to the year prior: report

Featured

AbbVie-bound Cerevel reports phase 3 Parkinson's victory in early win for $8.7B deal

By Nick Paul Taylor

The backing singer in AbbVie’s $8.7 billion takeover of Cerevel Therapeutics is having its moment in the spotlight.

Novo Nordisk attracts lawmakers' scrutiny after dropping discounted insulin product Levemir

By Fraiser Kansteiner

Novo Nordisk is receiving pushback from a trio of lawmakers on its decision to discontinue its long-acting insulin product Levemir, which was due for a steep discount at the start of the new year.

23andMine: CEO Anne Wojcicki aims to take genetics company private

By Conor Hale

23andMe’s co-founder and CEO Anne Wojcicki has put in motion a plan to take the company private after the stock value of the DNA testing provider has collapsed by more than 97% since its multibillion-dollar market debut just three years ago.

AACR: Biotechs emerge frostbitten from 'nuclear winter,' ready to show why they fought for survival

By Annalee Armstrong

A thinner, leaner biotech forest arrived at the American Association for Cancer Research conference in San Diego ready to showcase the budding data that has sprouted as a result of difficult decisions made during the sector’s so-called “nuclear winter.”

Lilly's Mounjaro, Zepbound supply situation worsens as most doses now face multi-month shortages

By Zoey Becker

The FDA now expects most doses of the drugs to be in "limited availability" through the second quarter. Just a few weeks ago, the agency projected the supply strain would ease ease in April.

With $290M in hand, newly emerged biotech Metsera thinks customizable combos are the future of obesity treatments

By Gabrielle Masson

Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines.

Biopharma M&A more than doubled in the first quarter compared to the year prior: report

By Max Bayer

Biopharma dealmaking continues to be one of the most encouraging signs of the industry's (partial) recovery. The number of deals in the first quarter more than doubled from the same period a year ago.

Bruker brokers $392M deal for frayed NanoString

By Conor Hale

Bruker has emerged as the winner of an auction for NanoString and its spatial biology tech after the company filed for Chapter 11 bankruptcy earlier this year.

AstraZeneca’s Alexion takes NMOSD awareness campaign long-form in new film highlighting community

By Andrea Park

Lights, camera, Alexion! Fresh off earning FDA approval for its drug Ultomiris to treat certain adults with neuromyelitis optica spectrum disorder, AstraZeneca’s rare disease unit has put out a short film sharing several NMOSD patients’ stories—and emphasizing the overlaps between them.

After coming up short in COVID, Valneva focuses on chikungunya vaccine launch

By Kevin Dunleavy

After striking out in an attempt to create a niche for its COVID-19 vaccine, Valneva is back to doing what it does best—developing, manufacturing and commercializing vaccines for a variety of infectious diseases with unmet needs. And its top priority is the launch of a chikungunya vaccine.

Vertex inches closer to acute pain market with FDA application acceptance

By Gabrielle Masson

Vertex Pharmaceuticals has inched closer to bringing a new, non-opioid med to the blockbuster pain market, with the FDA accepting a rolling new drug application for the company’s NaV1.8 inhibitor VX-548 in moderate-to-severe acute pain.

Fierce podcasts

Don’t miss an episode

'Podnosis': Inside Morgan Health’s investment strategy and the art of the pitch

Morgan Health has been investing in multiple businesses over the past three years that have the potential to improve employer-sponsored healthcare. This week on “Podnosis,” Paige Minemyer from Fierce Healthcare interviews Morgan Health Partner Dan Hartman about the company's investment strategy and how to make a memorable pitch.

Deep dive: Biopharma layoffs in Q1

Seen and unseen: A closer look at barriers to inclusive care for trans men

Resources

Whitepaper

Antibody Profiling: Decoding the Humoral Immune System

Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your FREE white paper today!

Straight to Market in an Autoinjector

The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors.

Presented by Lonza

eBook

Discover the future of mAb manufacturing

Unlock the future of mAb manufacturing with our complete guide to integrating the revolutionary Gibco™ Efficient-Pro™ Medium and Feeds System, enhancing productivity and quality for exceptional outcomes

Oncology Market Outlook 2024

This paper assesses the current state of the oncology market, reviewing key expectations for 2024. It addresses CAR-T therapies, KRAS, radiopharmaceuticals, & targeted protein degradation.

Presented by Blue Matter, strategic consultants in the life sciences

Whitepaper

Guidance for Biotechs Choosing Next-Gen Contract GMP/CMC Labs

Choosing the right contract lab can help drug developers accelerate their timelines and generate cost-efficiencies. For insights into what to look for when selecting a GMP/CMC lab partner read this white paper which delves into a range of factors that can support your needs in both the short-term and in planning for the future.

Sponsored by: PPD®️ Laboratory Services